- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01315652
Interest of a Standardized Monitoring of Rheumatoid Arthritis: The COMEDRA Trial (COMEDRA)
August 29, 2025 updated by: Assistance Publique - Hôpitaux de Paris
Evaluation of the Usefulness of a Center Specialized in the Standardized Management of Rheumatoid Arthritis: The COMEDRA Trial
The two objectives of this trial are :1 To evaluate the impact of a visit with a nurse checking the preventive modalities and/or the presence of comorbidities such as infections ( e.g.
vaccinations), cardiovascular-diseases (e.g.
Indication to statin, antiaggregant,anti-hypertensive treatment…), cancers (e.g.mammography,…), osteoporosis (e.g.
bone densitometry,..) in patients suffering from Rheumatoid Arthritis 2 To evaluate the impact of an educational program aimed at permitting rheumatoid arthritis patients to auto-evaluate their disease activity by collecting the Disease Activity Score (DAS28-ESR).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Patients with a stable definite Rheumatoid Arthritis will be invited by their rheumatologists to participate at this study in 20 centers in France. After written informed consent will be obtained, the patients will be randomized in two arms:
- comorbidities
- auto-DAS The patients will be seen again in the same center six months later in order to collect the outcome measures.
Study Type
Interventional
Enrollment (Actual)
970
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Paris, France, 75014
- Hopital Cochin
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Rheumatoid Arthritis
- Stable (no change in therapy)
- Adult
- Able to collaborate
Exclusion criteria
- Pregnant woman
- Change of the therapy for 3 months before the inclusion
- Alcoholism, toxicomania, psychological problem, sever co morbidity which could invalid the consent or limit the protocol compliance
- No social coverage affiliate
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Auto DAS
"Auto-DAS"Number of patients with a modification in their treatment between baseline and 6 months visits
|
"Auto-DAS"Number of patients with a modification in their treatment between baseline and 6 months visits
|
|
Active Comparator: Comorbidities treatment
|
" Comorbidities treatment":Number of actions initiated in order to treat or prevent Rheumatoid Arthritis comorbidities during the 6 months follow-up
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comorbidities treatment
Time Frame: 6 months later
|
Number of actions initiated I order to treat or prevent Rheumatoid Arthritis comorbidities
|
6 months later
|
|
Auto-DAS: Patient education to calculate his Disease Activity Score
Time Frame: 6 months after
|
Number of patients with a modification in their treatment between baseline and 6 months visits
|
6 months after
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Frequency of comorbidities in Rheumatoid Arthritis
Time Frame: 6 months later
|
6 months later
|
|
Adhesion to the current recommendations concerning the prevention of co-morbidities
Time Frame: 6 months later
|
6 months later
|
|
Compliance and satisfaction of the patients concerning the DAS educational program
Time Frame: 6 months later
|
6 months later
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Maxime Dougados, MD, PhD, Assistance Publique - Hôpitaux de Paris
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Tournadre A, Pereira B, Gossec L, Soubrier M, Dougados M. Impact of comorbidities on fatigue in rheumatoid arthritis patients: Results from a nurse-led program for comorbidities management (COMEDRA). Joint Bone Spine. 2019 Jan;86(1):55-60. doi: 10.1016/j.jbspin.2018.06.010. Epub 2018 Jul 17.
- Ferreira RJO, Dougados M, Kirwan JR, Duarte C, de Wit M, Soubrier M, Fautrel B, Kvien TK, da Silva JAP, Gossec L; CoimbRA investigators, RAID investigators and COMEDRA investigators. Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. Rheumatology (Oxford). 2017 Sep 1;56(9):1573-1578. doi: 10.1093/rheumatology/kex211.
- Dougados M, Soubrier M, Perrodeau E, Gossec L, Fayet F, Gilson M, Cerato MH, Pouplin S, Flipo RM, Chabrefy L, Mouterde G, Euller-Ziegler L, Schaeverbeke T, Fautrel B, Saraux A, Chary-Valckenaere I, Chales G, Dernis E, Richette P, Mariette X, Berenbaum F, Sibilia J, Ravaud P. Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA). Ann Rheum Dis. 2015 Sep;74(9):1725-33. doi: 10.1136/annrheumdis-2013-204733. Epub 2014 May 28.
- Gossec L, Soubrier M, Foissac F, Molto A, Richette P, Beauvais C, Ruyssen-Witrand A, Perdriger A, Chary-Valckenaere I, Mouterde G, Dernis E, Euller-Ziegler L, Flipo RM, Gilson M, Guis S, Mariette X, Pouplin S, Marhadour T, Schaeverbeke T, Sordet C, Fayet F, Dougados M. Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients. RMD Open. 2019 Jun 14;5(2):e000914. doi: 10.1136/rmdopen-2019-000914. eCollection 2019.
- Gossec L, Fayet F, Soubrier M, Foissac F, Molto A, Richette P, Beauvais C, Ruyssen-Witrand A, Perdriger A, Chary-Valckenaere I, Mouterde G, Dernis E, Euller-Ziegler L, Flipo RM, Gilson M, Balandraud N, Mariette X, Pouplin S, Marhadour T, Schaeverbeke T, Sordet C, Dougados M. Is self-assessment by patients of disease activity acceptable over the long term in rheumatoid arthritis? A 3-year follow-up of 771 patients. Rheumatology (Oxford). 2019 Aug 1;58(8):1498-1499. doi: 10.1093/rheumatology/kez094. No abstract available.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2011
Primary Completion (Actual)
October 1, 2015
Study Completion (Actual)
January 1, 2016
Study Registration Dates
First Submitted
March 9, 2011
First Submitted That Met QC Criteria
March 14, 2011
First Posted (Estimated)
March 15, 2011
Study Record Updates
Last Update Posted (Estimated)
September 5, 2025
Last Update Submitted That Met QC Criteria
August 29, 2025
Last Verified
August 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P100113
- P140101 (Other Identifier: AP-HP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
Yuanyuan ZhangRecruitingRheumatoid Arthritis (RA) | Rheumatoid Arthritis-Associated Interstitial Lung Disease | Difficult-to-Treat Rheumatoid ArthritisChina
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Richard Burt, MDTerminated
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
University Hospital, ToulouseCompletedRheumatoId ArthritisFrance
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on Auto-DAS
-
Philips RespironicsCompletedSleep Disordered Breathing | Sleep Apnea, CentralUnited States
-
Philips RespironicsCompletedObstructive Sleep ApneaUnited States, Germany
-
MetroHealth Medical CenterResMed; Great Lakes NeuroTechnologies Inc.TerminatedObstructive Sleep ApneaUnited States
-
McGill University Health Centre/Research Institute...Canadian Institutes of Health Research (CIHR); American Thoracic SocietyCompletedParkinson's Disease | Obstructive Sleep ApneaCanada
-
CelltrionCompletedModerately to Severely Active Rheumatoid ArthritisPoland
-
Somnetics International, Inc.CompletedObstructive Sleep ApneaUnited States
-
Children's Hospital Medical Center, CincinnatiCompletedObstructive Sleep ApneaUnited States
-
DAS-MG, IncTerminatedMyasthenia GravisUnited States
-
University Hospital, Clermont-FerrandTerminatedKeratoconus in One or Two Eyes for Case | Good Visual Acuity for ControlFrance
-
University of MichiganResMed FoundationCompleted